We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was one ...

Eli Lilly is a safer way to capitalize on AI-driven drug discovery.

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13 ...

On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, ...

Nvidia’s forthright ambitions to expand its drug development footprint are coming into focus, with the global computing powerhouse announcing a trio of new initiatives including a new collaboration ...

Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. The opportunity to explore a multi-genre universe in innovative ways is extremely exciting. Matt ...

Before biopharmaceutical companies raise money from venture capital firms, their early funding often comes from the U.S. government in the form National Institutes of Health grants. That was the case ...

As of Wednesday, December 17, Recursion Pharmaceuticals, Inc.’s RXRX share price has surged by 13.10%, which has investors questioning if this is right time to sell.